E3 ubiquitin ligases in ErbB receptor quantity control

被引:35
作者
Carraway, Kermit L., III [1 ]
机构
[1] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA
关键词
ErbB receptor; E3 ubiqutin ligase; Ubiquitination; Degradation; Cancer; GROWTH-FACTOR RECEPTOR; MAMMARY-GLAND DEVELOPMENT; END RULE PATHWAY; BREAST-CANCER; DOWN-REGULATION; C-CBL; PHOSPHATIDYLINOSITOL; 3-KINASE; SELECTIVELY TARGETS; NEU PROTOONCOGENE; PROTEIN STABILITY;
D O I
10.1016/j.semcdb.2010.09.006
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Signaling through ErbB family growth factor receptor tyrosine kinases is necessary for the development and homeostasis of a wide variety of tissue types. However, the intensity of receptor-mediated cellular signaling must fall within a precise range; insufficient signaling can lead to developmental abnormalities or tissue atrophy, while over-signaling can lead to hyperplastic and ultimately neoplastic events. While a plethora of mechanisms have been described that regulate downstream signaling events, it appears that cells also utilize various mechanisms to regulate their ErbB receptor levels. Such mechanisms are collectively termed "ErbB receptor quantity control." Notably, studies over the past few years have high-lighted roles for post-transcriptional processes, particularly protein degradation, in ErbB quantity control. Here the involvement of ErbB-directed E3 ubiquitin ligases is discussed, including Nrdp1-mediated ErbB3 degradation, ErbB4 degradation mediated by Nedd4 family E3 ligases, and CHIP-mediated ErbB2 degradation. The hypothesis is forwarded that protein degradation-based ErbB quantity control mechanisms play central roles in suppressing receptor overexpression in normal cells, and that the loss of such mechanisms could facilitate the onset or progression of ErbB-dependent tumors. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:936 / 943
页数:8
相关论文
共 113 条
[1]  
ALIMANDI M, 1995, ONCOGENE, V10, P1813
[2]   Amino-terminal dimerization, NRDP1-rhodanese interaction, and inhibited catalytic domain conformation of the ubiquitin-specific protease 8 (USP8) [J].
Avvakumov, George V. ;
Walker, John R. ;
Xue, Sheng ;
Finerty, Patrick J., Jr. ;
Mackenzie, Farrell ;
Newman, Elena M. ;
Dhe-Paganon, Sirano .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (49) :38061-38070
[3]   Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 [J].
Baselga, Jose ;
Swain, Sandra M. .
NATURE REVIEWS CANCER, 2009, 9 (07) :463-475
[4]  
Baulida J, 1996, J BIOL CHEM, V271, P5251
[5]  
BERGER MS, 1988, CANCER RES, V48, P1238
[6]   The role of protease activity in ErbB biology [J].
Blobel, Carl R. ;
Carpenter, Graham ;
Freeman, Matthew .
EXPERIMENTAL CELL RESEARCH, 2009, 315 (04) :671-682
[7]   Cellular functions of the BRCA tumour-suppressor proteins [J].
Boulton, S. J. .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2006, 34 :633-645
[8]   Structure-based mutagenesis of the substrate-recognition domain of Nrdp1/FLRF identifies the binding site for the receptor tyrosine kinase ErbB3 [J].
Bouyain, Samuel ;
Leahy, Daniel J. .
PROTEIN SCIENCE, 2007, 16 (04) :654-661
[9]  
Britsch S, 2007, V190
[10]   Neuregulins and their receptors: A versatile signaling module in organogenesis and oncogenesis [J].
Burden, S ;
Yarden, Y .
NEURON, 1997, 18 (06) :847-855